Most physiological PRL actions on the mammary gland are mediated through the JAK2/STAT5 pathway [35], and in breast cancer, activated STAT5 predicts sensitivity to estrogen targeted therapies and favorable clinical outcomes [36–38]. The gene discussed is JAK2; the disease is breast cancer.